Skip to Content

Oncternal Therapeutics Inc ONCT

Morningstar Rating
$7.08 −0.22 (3.01%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ONCT is trading at a 843% premium.
Price
$7.27
Fair Value
$82.54
Uncertainty
Extreme
1-Star Price
$823.96
5-Star Price
$3.23
Economic Moat
Rmjht
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONCT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$7.30
Day Range
$7.007.40
52-Week Range
$5.5713.14
Bid/Ask
$7.03 / $7.50
Market Cap
$20.95 Mil
Volume/Avg
8,214 / 5,728

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.64%

Company Profile

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
27

Competitors

Valuation

Metric
ONCT
LLY
MRK
Price/Earnings (Normalized)
100.7057.80
Price/Book Value
0.9466.177.87
Price/Sales
23.675.20
Price/Cash Flow
98.3918.29
Price/Earnings
ONCT
LLY
MRK

Financial Strength

Metric
ONCT
LLY
MRK
Quick Ratio
4.540.680.68
Current Ratio
4.661.351.25
Interest Coverage
14.113.97
Quick Ratio
ONCT
LLY
MRK

Profitability

Metric
ONCT
LLY
MRK
Return on Assets (Normalized)
−67.41%11.20%5.22%
Return on Equity (Normalized)
−78.35%57.69%13.56%
Return on Invested Capital (Normalized)
−83.00%20.65%8.29%
Return on Assets
ONCT
LLY
MRK
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
LmhwlckdjsHxcg$631.0 Bil
Vertex Pharmaceuticals Inc
VRTX
DxngcgbjsBhypcpt$126.2 Bil
Regeneron Pharmaceuticals Inc
REGN
RfxjhtmMqzpdn$120.7 Bil
Moderna Inc
MRNA
ShbfxhwncVwg$48.0 Bil
Alnylam Pharmaceuticals Inc
ALNY
RcxrxklYjqqgl$31.6 Bil
argenx SE ADR
ARGX
WyphzzftDpv$27.9 Bil
BioNTech SE ADR
BNTX
XllrknjCksz$20.9 Bil
Biomarin Pharmaceutical Inc
BMRN
CkbbshbdqQnkrgbk$16.3 Bil
United Therapeutics Corp
UTHR
QzsslngcZqgwv$14.6 Bil
Incyte Corp
INCY
BnyvfwqqFwkrz$12.6 Bil

Sponsor Center